UA118610C2 - Спіроциклічні інгібітори катепсину c - Google Patents

Спіроциклічні інгібітори катепсину c

Info

Publication number
UA118610C2
UA118610C2 UAA201703350A UAA201703350A UA118610C2 UA 118610 C2 UA118610 C2 UA 118610C2 UA A201703350 A UAA201703350 A UA A201703350A UA A201703350 A UAA201703350 A UA A201703350A UA 118610 C2 UA118610 C2 UA 118610C2
Authority
UA
Ukraine
Prior art keywords
cathepsin
inhibitors
same
spirocyclic
spirocyclic inhibitors
Prior art date
Application number
UAA201703350A
Other languages
English (en)
Inventor
Віктор Вінтоняк
Маттіас Грауерт
Марк Грундль
Александер Пауч
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA118610C2 publication Critical patent/UA118610C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Даний винахід стосується сполуки формули І: , І де А і Су мають одне зі значень, зазначених в описі, й їх застосування як інгібіторів катепсину С, до фармацевтичних композицій, які її містять, і до способів її застосування як засобів для лікування і/або попередження захворювань, пов'язаних з активністю дипептидилпептидази І, наприклад респіраторних захворювань.
UAA201703350A 2014-09-12 2015-09-08 Спіроциклічні інгібітори катепсину c UA118610C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Publications (1)

Publication Number Publication Date
UA118610C2 true UA118610C2 (uk) 2019-02-11

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201703350A UA118610C2 (uk) 2014-09-12 2015-09-08 Спіроциклічні інгібітори катепсину c

Country Status (34)

Country Link
US (3) US9540373B2 (uk)
EP (2) EP3191487B1 (uk)
JP (2) JP2017526716A (uk)
KR (1) KR102510588B1 (uk)
CN (2) CN108047240B (uk)
AP (1) AP2017009733A0 (uk)
AU (1) AU2015314355B2 (uk)
BR (1) BR112017003433B1 (uk)
CA (1) CA2960916C (uk)
CL (1) CL2017000432A1 (uk)
CO (1) CO2017002268A2 (uk)
CY (1) CY1123033T1 (uk)
DK (1) DK3191487T3 (uk)
EA (1) EA031376B1 (uk)
ES (1) ES2749009T3 (uk)
HK (1) HK1255362A1 (uk)
HR (1) HRP20191756T1 (uk)
HU (1) HUE047208T2 (uk)
IL (1) IL250262B (uk)
LT (1) LT3191487T (uk)
MX (2) MX367316B (uk)
MY (1) MY188382A (uk)
NZ (1) NZ728684A (uk)
PE (1) PE20170438A1 (uk)
PH (1) PH12017500453B1 (uk)
PL (1) PL3191487T3 (uk)
PT (1) PT3191487T (uk)
RS (1) RS59444B1 (uk)
SA (1) SA517381064B1 (uk)
SG (1) SG11201701633SA (uk)
SI (1) SI3191487T1 (uk)
TW (1) TWI687424B (uk)
UA (1) UA118610C2 (uk)
WO (1) WO2016038007A1 (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
NO2699580T3 (uk) 2014-01-24 2018-02-24
JP6529575B2 (ja) * 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
JP2017526716A (ja) 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
JP2021512904A (ja) * 2018-02-07 2021-05-20 インスメッド インコーポレイテッド Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
KR20230117738A (ko) * 2020-12-04 2023-08-09 레이스톤 바이오파마 컴퍼니 리미티드 카텝신 c의 소분자 억제제 및 이의 의약적 용도
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE60229114D1 (en) 2001-03-02 2008-11-13 Axys Pharm Inc Cathepsincystein-proteasehemmer
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
DK2032535T3 (da) * 2006-06-01 2012-11-05 Sanofi Sa Spiro-cycliske nitriler som protease-inhibitorer
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
JP5240201B2 (ja) 2007-10-12 2013-07-17 富士通株式会社 Ｉｐ電話自動試験システム及び方法
AU2008334444B2 (en) 2007-12-12 2011-12-15 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors
CN102574830A (zh) 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
SG11201406274VA (en) 2012-04-27 2014-11-27 Glaxo Group Ltd Novel compounds
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
WO2013177224A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN105102456B (zh) 2012-09-28 2017-11-14 癌症研究技术有限公司 非典型蛋白激酶c的氮杂喹唑啉抑制剂
US20140100236A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
UA115074C2 (uk) 2012-10-15 2017-09-11 Епізайм, Інк. Бензольні сполуки, що містять замісники
PL2909192T3 (pl) 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
EP2917221A1 (en) 2012-11-01 2015-09-16 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
CA2895239C (en) 2012-12-21 2020-10-27 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
MX361375B (es) 2013-03-14 2018-12-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano.
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
US8877775B2 (en) * 2013-03-14 2014-11-04 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SG11201507382QA (en) 2013-03-14 2015-10-29 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
KR101886550B1 (ko) * 2014-04-29 2018-08-07 케어베이 유럽 리미티드 바늘 삽입 깊이를 조정하기 위한 장치
CN106660409A (zh) 2014-07-03 2017-05-10 普利司通美国轮胎运营有限责任公司 轮辋保护装置的侧壁装饰
JP2017526716A (ja) * 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
HUE041694T2 (hu) 2014-09-12 2019-05-28 Glaxosmithkline Ip No 2 Ltd Tetrahidrokvinolin származékok mint bromodomén inhibitorok

Also Published As

Publication number Publication date
CN107074870A (zh) 2017-08-18
EP3191487A1 (en) 2017-07-19
US9540373B2 (en) 2017-01-10
ES2749009T3 (es) 2020-03-18
EA201790576A1 (ru) 2017-08-31
CA2960916C (en) 2023-03-07
CN108047240B (zh) 2020-08-04
MX2019009695A (es) 2019-10-07
CN107074870B (zh) 2019-07-12
US20160075704A1 (en) 2016-03-17
IL250262A0 (en) 2017-03-30
MY188382A (en) 2021-12-07
CL2017000432A1 (es) 2017-10-20
KR102510588B1 (ko) 2023-03-17
SI3191487T1 (sl) 2019-12-31
US20170073352A1 (en) 2017-03-16
PL3191487T3 (pl) 2020-03-31
SA517381064B1 (ar) 2021-02-07
TWI687424B (zh) 2020-03-11
LT3191487T (lt) 2019-10-10
PT3191487T (pt) 2019-11-18
AU2015314355B2 (en) 2019-06-20
TW201625647A (zh) 2016-07-16
RS59444B1 (sr) 2019-11-29
PH12017500453A1 (en) 2017-07-31
WO2016038007A1 (en) 2016-03-17
US9879026B2 (en) 2018-01-30
USRE47636E1 (en) 2019-10-08
AU2015314355A1 (en) 2017-02-16
IL250262B (en) 2020-03-31
PE20170438A1 (es) 2017-04-28
EP3511331A1 (en) 2019-07-17
CN108047240A (zh) 2018-05-18
DK3191487T3 (da) 2019-10-28
EP3191487B1 (en) 2019-08-07
BR112017003433B1 (pt) 2023-11-14
MX2017003156A (es) 2017-05-23
KR20170054489A (ko) 2017-05-17
HRP20191756T1 (hr) 2019-12-27
AP2017009733A0 (en) 2017-02-28
JP2018044011A (ja) 2018-03-22
HUE047208T2 (hu) 2020-04-28
HK1255362A1 (zh) 2019-08-16
MX367316B (es) 2019-08-15
EA031376B1 (ru) 2018-12-28
CO2017002268A2 (es) 2017-06-20
JP2017526716A (ja) 2017-09-14
NZ728684A (en) 2022-09-30
CA2960916A1 (en) 2016-03-17
CY1123033T1 (el) 2021-10-29
BR112017003433A2 (pt) 2017-11-28
JP6360961B2 (ja) 2018-07-18
PH12017500453B1 (en) 2017-07-31
SG11201701633SA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
PH12017500453B1 (en) Spirocyclic inhibitors of cathepsin c
MX2020006438A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
PH12017501921A1 (en) Novel compounds
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12016501750A1 (en) Human plasma kallikrein inhibitors
TN2015000278A1 (en) Autotaxin inhibitors
NZ720478A (en) Autotaxin inhibitor compounds
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
PH12014502065A1 (en) Vesicular formulations
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.